Saturday 17 October 2026
Export MRNA’s income statement to Excel — free account
Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
218.01
18.49
−7.82%
Follow MRNA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.51 | 9.02 | 5.90 | 4.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(52.99) | (31.85) | 12.34 | (11.89) | |
P/B ratio |
4.12 | 2.71 | 1.33 | 1.08 | |
Price to Tangible BV |
4.12 | 2.71 | 1.33 | 1.08 | |
EV/Sales |
10.47 | 6.95 | 3.23 | 2.51 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(21.74) | (10.55) | (3.35) | (2.83) | |
EV/FCF |
(18.75) | (9.65) | (3.03) | (2.10) | |
Quick Ratio |
2.03 | 2.20 | 3.01 | 3.30 | |
Current Ratio |
2.29 | 2.41 | 3.29 | 3.93 | |
Net Debt/EBITDA |
5.96 | 3.43 | 6.46 | 19.90 | |
Debt/Assets |
5.45% | 5.25% | 4.94% | 0.21% | |
Debt/Equity |
0.09 | 0.08 | 0.07 | 0.00 | |
Asset Turnover |
0.19 | 0.18 | 0.15 | 0.16 | |
Operating CF/Net income |
0.67 | 0.47 | (1.13) | 4.24 | |
Capex/Depreciation |
(0.70) | (1.29) | (0.72) | (0.94) | |
Research and Development Expense of Revenue |
448.97% | 166.84% | 114.31% | 78.84% | |
Selling, General and Administrative Expense of Revenue |
148.97% | 44.47% | 45.43% | 26.38% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
82.76% | 26.74% | 16.67% | 12.30% | |
Graham Net Nets |
0.06 | 0.08 | 0.25 | 0.38 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.41%) | (16.04%) | (24.65%) | (31.24%) | |
Free Cash Flow Yield |
(4.46%) | (7.99%) | (18.09%) | (26.44%) | |
Revenue per Share |
0.36 | 0.98 | 1.74 | 2.61 | |
Operating CF per Share |
(1.32) | (1.59) | 2.39 | (2.17) | |
Capex per Share |
(0.09) | (0.16) | (0.10) | (0.08) | |
Free Cash Flow per Share |
(1.41) | (1.75) | 2.29 | (2.26) | |
Cash per Share |
12.91 | 13.18 | 14.91 | 11.55 | |
Shareholders Equity per Share |
16.99 | 18.75 | 22.24 | 23.92 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.99 | 18.75 | 22.24 | 23.92 | |
Free Cash Flow |
(563.00) | (692.00) | 891.00 | (880.00) | |
Working Capital |
3,281.00 | 3,375.00 | 4,557.00 | 4,917.00 | |
Capital Expenditures |
(37.00) | (62.00) | (39.00) | (33.00) | |
Net Current Asset Value |
1,615.00 | 1,690.00 | 2,856.00 | 3,793.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.26 | 0.16 | 0.06 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
26.50 | 74.50 | 271.00 | 1,305.00 | |
Average Payables |
171.00 | 193.50 | 361.00 | 320.00 | |
Average Inventory |
260.00 | 137.00 | 135.00 | 372.00 | |
Average Assets |
11,485.50 | 12,096.00 | 13,240.00 | 13,969.00 | |
Average Common Equity |
8,080.00 | 8,737.00 | 9,775.50 | 10,628.50 |
Columns are period end dates